What is GW 0742

GW 0742 is a selective PPARδ agonist (EC50 = 1.1 nM) that exhibits 1,000-fold selectivity over the other human PPAR subtypes. GW 0742 exhibits time-dependent neuroprotection in low KCl-induced apoptosis in cerebellar granule neuronal cultures. Despite the neuroprotective properties observed, prolonged (48h) incubation with GW 0742 produced significant inherent toxicity. This cell death was determined to be apoptotic as identified with the TUNEL assay.
 

Function:

GW 0742 activates AMP acti vated pro tein ki nase and stimulates glucose uptake in skeletal muscle tissue , and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome , most likely by stimulating fatty acid oxidation .

GW0742 has been proposed as a potential treatment for obesity and related conditions , especially when used in conjunction with a synergistic compound A I C A R , as the combination has been shown to significantly increase exercise endurance in human.

Application:

GW-0742 - promotion and growth of lean muscle tissue and mass. This is extremely important for the individual suffering from a muscle wasting disease. It is the muscle wasting that at times can lead to the demise of the patient even before the disease itself.

1) Increases in strength - again, excellent for those suffering from muscle wasting diseases. Increased bone density and strength - highly beneficial to the osteoporosis patient. S A R M S may prove to be one of if not the most effective osteoporosis treatments available, although official data is still inconclusive.
 
2) Fat Loss - medications with strong androgen binding affinity have been shown to promote lipolysis. How significant these six S A R M S are in this regard is inconclusive.
 
3) Low to No Virilization - this is highly important to women. Many compounds (anabolicandrogenic steroids) while the same benefits of ana bo lic steroid s can apply to women as they do men, there is often the issue of virilization.
 
4) Endurance & Conditioning - All of the pre-clinical S A R M S should have a level of positive effect on muscular endurance as well as overall physical conditioning. The level of effectiveness in such regards is dependent on the S A R M in question and data is still inconclusive to quantify the total effects.
 
5) Nutrient Efficiency - All of the pre-clinical S A R M S should have a positive impact on nutrient efficiency to one degree or another. This refers to the ability of the body to make better use of the nutrients it consumes.